Pfizer (PFE)
23.52
+0.52 (2.26%)
NYSE · Last Trade: May 20th, 6:35 PM EDT
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · May 20, 2025
Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.
Via Benzinga · May 20, 2025
The agency plans to demand stronger evidence of efficacy for the shots before approval is granted for healthy persons, between the ages of six months and 64 years, with no risk factors for severe COVID-19 infection.
Via Stocktwits · May 20, 2025
The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness.
Via Investor's Business Daily · May 20, 2025
The company said Tencent Cloud will allow it to offer localized and compliant cloud services in countries outside of China, accelerating the commercial rollout of its robotaxi services overseas.
Via Stocktwits · May 20, 2025
3SBio’s experimental cancer drug is currently undergoing clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.
Via Stocktwits · May 20, 2025
Indian markets ended sharply lower, dragged by broad-based profit booking, FPI outflows, and fading optimism over the U.S.-India trade deal.
Via Stocktwits · May 20, 2025
Via The Motley Fool · May 20, 2025
Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody SSGJ-707.
Via Benzinga · May 19, 2025
BrainStorm Cell Therapeutics plans to enroll 200 ALS patients in its FDA-cleared Phase 3b trial of NurOwn, with a 24-week double-blind phase followed by an open-label extension.
Via Stocktwits · May 19, 2025
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.
Via Benzinga · May 19, 2025
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase risk of severe illness.
Via Benzinga · May 19, 2025
A company with profits isn’t always a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Via StockStory · May 19, 2025
Via Stocktwits · May 19, 2025
The pharma company secured FDA clearance to manufacture and distribute its COVID-19 vaccine Nuvaxovid for adults and at-risk groups, with no advisory committee hurdles.
Via Stocktwits · May 18, 2025
Here are three dividend-paying stocks that warrant closer examination.
Via The Motley Fool · May 18, 2025
Via The Motley Fool · May 16, 2025
Profitability is a key measure of business strength.
Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline.
Via StockStory · May 16, 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.
Via Benzinga · May 15, 2025
Via The Motley Fool · May 15, 2025
Temporary turbulence has resulted in opportunity for patient, bargain-hunting investors.
Via The Motley Fool · May 14, 2025
Looking for the most active stocks in the S&P500 index on Wednesday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · May 14, 2025
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
Via Benzinga · May 14, 2025